RAGE fusion proteins, formulations, and methods of use thereof
US7981424B2 · kind B2 · utility
9Cited by
37References
52Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 25, 2007 |
| Grant date | Jul 19, 2011 |
| Priority date | — |
| Expiry date | Aug 11, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to the N-terminus of an immunoglobulin CH2 domain. Also disclosed are RAGE fusion protein formulations and the use of the RAGE fusion proteins and RAGE fusion protein formulations as therapeutics for RAGE-mediated pathologies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.